Mechanisms of ventricular rate adaptation as a predictor of arrhythmic risk

Esther Pueyo,1,2,3 Zoltán Husti,4 Tibor Hornyik,4,5 István Baczkó,4 Pablo Laguna,2,3 András Varró,4,5 and Blanca Rodríguez1

1Oxford University Computing Laboratory, University of Oxford, Oxford, United Kingdom; 2Instituto de Investigación en Ingeniería de Aragón, Universidad de Zaragoza, Zaragoza, Spain; 3Centro de Investigación Biomédica En Red de Bioingeniería, Biomateriales y Nanomedicina, Zaragoza, Spain; and 4Department of Pharmacology and Pharmacotherapy, University of Szeged, and 5Research Unit for Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary

Submitted 5 October 2009; accepted in final form 23 February 2010

Pueyo E, Husti Z, Hornyik T, Baczkó I, Laguna P, Varró A, Rodríguez B. Mechanisms of ventricular rate adaptation as a predictor of arrhythmic risk. Am J Physiol Heart Circ Physiol 298: H1577–H1587, 2010. First published March 5, 2010; doi:10.1152/ajpheart.00936.2009.—Protracted QT interval (QTI) adaptation to abrupt heart rate (HR) changes has been identified as a clinical arrhythmic risk marker. This study investigates the ionic mechanisms of QTI rate adaptation and its relationship to arrhythmic risk. Computer simulations and experimental recordings in human and canine ventricular tissue were used to investigate the ionic basis of QTI and action potential duration (APD) to abrupt changes in HR with a protocol commonly used in clinical studies. The time for 90% QTI adaptation is 3.5 min in simulations, in agreement with experimental and clinical data in humans. APD adaptation follows similar dynamics, being faster in midmyocardial cells (2.5 min) than in endocardial and epicardial cells (3.5 min). Both QTI and APD adapt in two phases following an abrupt HR change: a fast initial phase with time constant < 30 s, mainly related to L-type calcium and slow-delayed rectifier potassium current, and a second slow phase of > 2 min driven by intracellular sodium concentration ([Na+]i) dynamics. Alterations in [Na+]i dynamics due to Na+/K+ pump current inhibition result in protracted rate adaptation and are associated with increased proarrhythmic risk, as indicated by action potential triangulation and faster L-type calcium current recovery from inactivation, leading to the formation of early afterdepolarizations. In conclusion, this study suggests that protracted QTI adaptation could be an indicator of altered [Na+]i dynamics following Na+/K+ pump inhibition as it occurs in patients with ischemia or heart failure. An increased risk of cardiac arrhythmias in patients with protracted rate adaptation may be due to an increased risk of early afterdepolarization formation.

Characterization of Ventricular HR Adaptation Dynamics

The present study investigates the ionic basis of QTI rate adaptation in human ventricular tissue and its link to proarrhythmic mechanisms. Computer simulations and experiments were conducted to identify the specific mechanisms of ionic transport that determine QTI rate adaptation and how alterations in those mechanisms might result in arrhythmic events. Key simulation predictions were evaluated using experimental and clinical data from the literature and a limited set of experiments in humans performed in this study. Ionic mechanisms underlying HR adaptation were further investigated using simulations and experiments in both humans and dogs because of their similar repolarization mechanisms and the greater availability of canine tissue compared with that of humans (41).

MATERIALS AND METHODS

CLINICAL, EXPERIMENTAL, AND theoretical studies have shown that an abrupt change in heart rate (HR) results in the progressive adaptation of the QT interval (QTI) in the ECG because of short-term cardiac memory effects (2, 3, 22, 29, 35, 36). Patients exhibiting protracted QTI HR adaptation dynamics have been identified as at increased risk of experiencing cardiac arrhythmias and sudden cardiac death (22, 35). Furthermore, clinical data also suggest that the extent of amiodarone-induced acceleration of QTI HR adaptation could be used as a therapeutic marker of drug efficacy (37). However, despite strong evidence suggesting an important role of short-term cardiac memory in arrhythmogenesis, the underlying mechanisms are still controversial.

Address for reprint requests and other correspondence: E. Pueyo, Oxford Univ. Computing Lab., Wolfson Bldg., Parks Rd., Oxford OX1 3QD, UK (e-mail: epueyo@unizar.es).

http://www.ajpheart.org 0363-6135/10 $8.00 Copyright © 2010 the American Physiological Society
were quantified for control and also following ±15 and ±30% changes in specific model parameters. The arrhythmic risk markers (30) considered were 1) AP triangulation, quantified as δ = APD/APD_{iso} where APD_{iso} denotes APD at 50% repolarization, considered to be an indicator of an early afterdepolarization (EAD) occurrence (34); 2) APD restitution (APDR) curve slope at a diastolic interval of 60 ms (26), determined using both S1-S2 and dynamic protocols (38), S_{max}-S_{min} and S_{min}, respectively; and 3) calcium current reactivation, as the product p of the inactivation gates [f, f_{2}, and f_{calc} (38)] of the L-type calcium current (I_{CaL}) computed at 90% repolarization for steady state at a CL of 1,000 ms (42).

Experimental Methods

Experiments were performed to validate key simulation results, when specific data were not available in the literature. Experiments were conducted in human ventricular tissue when available (n = 2 tissue samples); otherwise, right ventricle papillary muscles isolated from adult mongrel dogs hearts (tissue samples) were used (8–20 kg, either sex) (40). All animal experiments were conducted in compliance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, Revised 1996), and the protocol was approved by the Ethical Committee for the Protection of Animals in Research of the University of Szeged, Hungary (I-74-125-2007) and by the Department of Animal Health and Food Control of the Ministry of Agriculture and Rural Development (XIII/01031/000/2008). Regard-
ing human experiments, undiseased human hearts that were techni-
cally not usable for transplantation (based on logistical and not on patient-related reasons) were obtained from general organ donors. Before cardiac explantation, organ donor patients did not receive medication except dobutamine, furosemide, and plasma expanders. The investigations conform with the principles outlined in the Dec-
laration of Helsinki of the World Medical Association. The experi-
mental procedures and protocols were approved by the Ethical Re-
view Board of the Medical Center of the University of Szeged, Hungary (No. 51-57/1997 OEJ). Human right ventricular papillary muscle preparations were dissected from donor hearts stored in cardioplegic solution at 4°C for 3 to 4 h before placing them into oxygenated modified Locke’s solution containing (in mM) 120 NaCl, 4 KCl, 1.0 CaCl₂, 1 MgCl₂, 22 NaHCO₃, and 11 glucose. The pH of this solution was set to 7.4 ± 0.05 when saturated with the mixture of 95% O₂ and 5% CO₂ at 37°C.

Transmembrane APs were recorded using the conventional micro-electrode technique as described previously (40). APD HR adaptation was evaluated using the same protocol as in the simulations, both in control (in humans and dogs) and in the presence of the following drug concentrations (in dogs): 0.2 and 0.6 µM strophanthin G (n = 5 and 7), 1 and 3 µM nisoldipine (n = 1), 30 µM BaCl₂ (n = 2), 0.25 µM HMR-1,556 (n = 3), and 0.1 µM dofetilide (n = 3). Strophanthin G and BaCl₂ were dissolved in distilled water to give stock solution concentrations of 1 and 50 mM, respectively. Nisoldipine was dis-
olved in 100% ethanol stock solution (1 mM). HMR-1,556 was dis-
olved in DMSO stock solution (1 mM).

RESULTS

Ventricular Rate Adaptation

QTI adaptation. Figure 1A illustrates QTI adaptation kinetics in humans from simulations (left) and clinical data (29) (right). Figure 1B shows simulated pECG for the first beat following HR acceleration (left) and deceleration (right) and when the new steady state is reached. QTI adaptation after a
step CL decrease/increase begins with a fast QTI shortening/lengthening during the initial beats after the HR change ($T_{fast} = 17/34$ s), followed by a second slow accommodation ($T_{slow} = 122/122$ s). In the simulations, the time ($t_{90}$) required for QTI to complete 90% of its adaptation in humans is 217/224 s following HR acceleration/deceleration. As shown in Fig. 1C, simulation values for $t_{90}$ are within the wide range reported clinically.

A sensitivity analysis was performed to assess the dependence of QTI rate adaptation dynamics on CL change magnitude ($m_{CL}$) and on the initial CL ($i_{CL}$). Values for $m_{CL}$ considered were 200, 400, and 600 ms, and values for $i_{CL}$ were 1,000 and 1,400 ms. No statistically significant differences (analysis of variance, $P > 0.05$) in $t_{90}$ are observed when varying $m_{CL}$ or $i_{CL}$.

**APD adaptation.** Figure 2, A and B, illustrates APD HR adaptation in simulated Endo (top), Mid (middle), and Epi (bottom) human ventricular cells. Figure 2A shows the time course of APD adaptation, and Fig. 2B illustrates the AP corresponding to the first beat and the new steady state following HR change.

<table>
<thead>
<tr>
<th>Simulation</th>
<th>APD ms</th>
<th>HR acc</th>
<th>HR dec</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENDO</td>
<td>300</td>
<td>216 s</td>
<td>224 s</td>
</tr>
<tr>
<td>MID</td>
<td>400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPI</td>
<td>300</td>
<td>213 s</td>
<td>218 s</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Experimental</th>
<th>TP06</th>
<th>Endo</th>
<th>HRacc: 216 s</th>
<th>HRdec: 224 s</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franz et al</td>
<td>Endo</td>
<td>HRcc: 108 s – 192 s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seed et al</td>
<td>Endo</td>
<td>HRcc: &gt; 180 s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>This study</td>
<td>Papillary</td>
<td>Muscle</td>
<td>HRcc: 89 s – 150 s</td>
<td>HRcc: 159 s – 327 s</td>
</tr>
</tbody>
</table>

**Fig. 2.** A: simulated action potential (AP) duration (APD) adaptation in humans for CL of 1,000 to 600 to 1,000 ms for endocardial (Endo; top), midmyocardial (Mid; middle), and epicardial (Epi; bottom) cardiomyocytes. B: simulated APs corresponding to first (dotted line) and last (solid line) beats after CL decrease (left) and CL increase (right) for human Endo (top), Mid (middle), and Epi (bottom) cardiomyocytes. C: experimental APD adaptation in humans for CL of 750–410 ms (left, modified and redrawn from original graphs from Ref. 18) and for CL of 1,000–600 ms (right, this study). D: $t_{90}$ values for simulated and experimental human APs.
ing HR acceleration (left) and deceleration (right) for the three cell types. Figure 2C presents experimental APD adaptation measured in human ventricular endocardium (18), as well as in human papillary muscle, measured in this study.

It is clear that APD HR adaptation dynamics are similar in human simulations and experiments (18) and comparable with QTI HR adaptation dynamics (shown in Fig. 1), consisting of a fast and slow phase (τ_{fast} = 13/26 s after CL decrease/increase for Endo, 6/14 s for Mid, and 13/26 s for Epi cells; and τ_{slow} = 126/122 s after CL decrease/increase for Endo, 128/122 s for Mid, and 126/123 s for Epi cells). This suggests that QTI HR adaptation is a manifestation of cellular APD HR adaptation. As shown in Fig. 2D, simulation values for t_{90} are within the range observed experimentally. Furthermore, simulations with both the human and the dog models yield similar rate adaptation dynamics, although slightly slower in dog (t_{90} = 282/311 s in canine and t_{90} = 213/218 s in human Epi cells for HR acceleration/deceleration, respectively). Analogous to the results reported for QTI in this study, no statistically significant differences in t_{90} for APD adaptation are found when varying m_{CL} or i_{CL}.

### Ionic Mechanisms of APD Rate Adaptation

Figures 3 and 4 illustrate the ionic mechanisms of APD HR adaptation in humans. Each panel in Fig. 3 represents the change in peak value of each ionic current [slow delayed rectifier potassium current (I_{Ks}), I_{CaL}, transient outward potassium current (I_{to}), rapid delayed rectifier potassium current (I_{Kr}), inward rectifier potassium current (I_{K1}), fast sodium current (I_{Na}), Na^{+}/Ca^{2+} exchanger current (I_{NaCa}), and Na^{+}/K^{+} pump current (I_{NaK})] or intracellular sodium and calcium ion concentration ([Na^{+}]_{i} and [Ca^{2+}]_{i}), as a function of APD during HR acceleration (analogous results were obtained for HR deceleration; graphics not shown). The numbers shown in each graph indicate the number of beats following the CL change. Bar graphs in Fig. 4 show the percentage of total change in peak values of each ionic current or intracellular ion concentration that occurred during the fast (top) and slow (bottom) phase of HR adaptation. The ionic mechanisms involved in each of the adaptation phases, fast and slow, are further described in the following.

**Initial fast phase of adaptation.** Figures 3 and 4 show that I_{CaL} and I_{Ks} experience the greatest percentage of total change during the initial phase of rate adaptation and are key mechanisms driving that phase. Other ionic currents, such as I_{to}, present a percentage of change similar to I_{Ks}, but these changes are a consequence (and not a cause) of APD adaptation, since variations in conductance and/or kinetics do not affect τ_{fast}.

Figure 5A further illustrates the role that the dynamics of the I_{CaL} slow voltage-dependent inactivation gate (f) and the I_{Ks}...
activation gate \((xs)\) play in the fast phase of human APD adaptation. Indeed, a sudden decrease in CL results in an insufficient time for \(f\) to fully recover \((f < 1)\) (Fig. 5A, top), whereas \(I_{Ks}\) is unable to completely deactivate \((xs > 0)\) at the end of each beat. The resulting decrease in inward and increase in outward currents contribute to APD shortening following HR acceleration. To further illustrate the importance of \(f\) and \(xs\) in the initial adaptation phase, Fig. 5A, right, shows APD adaptation dynamics for control and for a simulation where beat-to-beat differences in \(f\) and \(xs\) are eliminated by fixing them to their steady-state values for a CL of 1,000 ms \((f = 0.9774\) and \(xs = 0.003225\), respectively). Results show that eliminating beat-to-beat differences in \(f\) and \(xs\) leads to the abolishment of the fast phase of APD adaptation. Similar mechanisms are observed using the canine ventricular model (not shown).

Simulations were performed to evaluate the effect of moderate changes \((\pm 15–30\%)\) in values of key parameters defining gate kinetics and conductances of all ionic currents in the human ventricular model. The effect of those changes on time constants for the fast and slow adaptation phases \((\tau_{fast}\) and \(\tau_{slow}\)) as well as the arrhythmic risk indicators \(\rho, \delta, S_{S1-S2}\) and \(S_{dyn}\), were quantified. Simulation results are shown in Fig. 6 for the parameters with greatest influence on human APD HR adaptation. As previously discussed and illustrated in Figs. 3–5, Fig. 6 \((first\ row)\) also shows that \(\tau_{fast}\) is greatly sensitive to \(I_{Cal}\) inactivation and \(I_{Ks}\) activation kinetics and thus moderate changes of up to 30\% in \(\tau_{fast}\) significantly alter \(\tau_{slow}\). Changes of up to 30\% in ionic current conductances have only a negligible effect on \(\tau_{fast}\) \((first\ row)\). Additional simulations and experiments were conducted to evaluate whether large degrees \((>70\%)\) of ion channel block could affect \(\tau_{fast}\). Results for human ventricular myocyte simulations and canine experiments are shown in Fig. 7, left and right, respectively, for \(I_{Cal}\) \((A)\), \(I_{Ks}\) \((B)\), \(I_{K1}\) \((C)\), and \(I_{Ks}\) \((D)\). Results show that \(I_{Cal}\) block by 70–90\% significantly increases \(\tau_{fast}\) by 54–249/107–223\% following HR acceleration/deceleration using the human model \((Fig. 7A, left)\). Qualitatively similar results are obtained using the canine model (not shown), although the effects are more pronounced in dogs, reaching >500\% change in \(\tau_{fast}\) for full \(I_{Cal}\) block. In the experiments, \(I_{Cal}\) block using 1 or 3 \(\mu\)M nisoldipine also results in increased \(\tau_{fast}\) in canine papillary muscle \((Fig. 7A, right)\), although to a lower extent than in the simulations, i.e., by 33/72\% and 54/94\% following HR acceleration/deceleration, respectively.

Furthermore, simulated 90–100\% \(I_{Ks}\) inhibition results in a significant decrease in \(\tau_{fast}\) by 71–82/63–76\% following HR acceleration/deceleration in humans \((Fig. 7B, left)\), whereas in dogs, the simulated effect is <10\%. In the canine experiments, \(I_{Ks}\) block by 0.25 \(\mu\)M HMR-1556 \((\approx\) full block) led to 16/20\% increase in \(\tau_{fast}\) following HR acceleration/deceleration \((Fig. 7B, right)\). The effect of \(I_{K1}\) and \(I_{Ks}\) block on \(\tau_{fast}\) was also explored. The results in Fig. 7C, left, show that simulated \(I_{K1}\) block by 80–90\% results in a 6–40/3–22\% increase in \(\tau_{fast}\) following HR acceleration/deceleration in humans, whereas in dogs it results in a 39–67/41–67\% decrease in \(\tau_{fast}\). In the experiments, 30 \(\mu\)M BaCl\(_2\) (estimated 80\% block) results in a 28/11\% decrease in \(\tau_{fast}\) \((Fig. 7C, right)\). Full \(I_{Ks}\) block results in a 7/9\% increase in \(\tau_{fast}\) with the human model \((Fig. 7D, left)\), but in the canine model this leads to EADs, making the \(\tau_{fast}\) measurement impossible. In the canine experiments with 0.1 \(\mu\)M dofetilide, there is a 10/10\% decrease in \(\tau_{fast}\) following HR acceleration/deceleration \((Fig. 7D, right)\). Overall, the simulations and experiments show a good qualitative agreement in the
effect of specific ionic current block on $\tau_{\text{fast}}$, although specific quantitative differences are found, which are further analyzed in DISCUSSION.

Slow phase of adaptation. APD adaptation finishes with a slow phase, during which $[\text{Na}^+]_i$ and $[\text{Ca}^{2+}]_i$, as well as $I_{\text{NaK}}$, $I_{\text{NaCa}}$, and several potassium currents, experience important changes (Figs. 3 and 4). As shown in Fig. 5B, left, following HR acceleration, $[\text{Na}^+]_i$ slowly accumulates (control trace), which causes an increase in repolarization current via enhanced activity of $I_{\text{NaK}}$ and $I_{\text{NaCa}}$ (operating in reverse mode), resulting in a progressive APD shortening. With the use of both human and canine ventricular models, clamping $[\text{Na}^+]_i$ to its steady-state value eliminates the slow APD adaptation phase (Fig. 5B, left). This suggests that $[\text{Na}^+]_i$ dynamics determine the slow phase of adaptation and that changes in potassium currents depicted in Figs. 3 and 4 are secondary to APD alterations caused by sodium regulation.

The results in Fig. 6 confirm the importance of $I_{\text{NaK}}$ in the slow phase of APD adaptation: $I_{\text{NaK}}$ maximal conductance is the only model parameter that when altered moderately (up to 30%) exerts a significant influence in $r_{\text{slow}}$ in both humans and dogs. Figure 8A shows that $I_{\text{NaK}}$ inhibition by 30% results in an increase in $r_{\text{slow}}$ by $\sim 60\%$ in virtual humans (Fig. 8A, left) and by $\sim 150\%$ in virtual canine Epi myocytes, whereas 0.6 $\mu$M strophanthin G results in an $\sim 100\%$ increase in $r_{\text{slow}}$ in canine experiments (Fig. 8A, right). $I_{\text{Kf}}$ and $I_{\text{Ks}}$ block are also found to have an impact on the slow APD adaptation, although only in dogs, not in humans, and only for almost complete block. Specifically, 90% $I_{\text{Kf}}$ block leads to a $>30\%$ decrease in $r_{\text{slow}}$ in both simulations and experiments in dogs but only to a $\sim 10\%$ decrease in human simulations. Full $I_{\text{Ks}}$ block is associated with $>25\%$ increase in $r_{\text{slow}}$ in experiments in dogs but results in $<10\%$ change in $r_{\text{slow}}$ in humans. The effects of $I_{\text{CaL}}$ or $I_{\text{Kr}}$ block on $r_{\text{slow}}$ are negligible.

APD HR Adaptation and Arrhythmic Risk

In this section, the link between protracted QTI and APD HR adaptation dynamics and arrhythmic risk suggested by clinical studies (19, 35) is investigated. As shown in Fig. 6, fast $I_{\text{CaL}}$ inactivation and $I_{\text{Kr}}$ activation (i.e., decrease in $r_f$ or $r_{xs}$, respectively) lead to large $r_{\text{fast}}$ values and to a simultaneously flattening of restitution curves, an enhanced AP triangulation (associated with increased risk of EAD development), and a decrease and an increase in $\rho$, respectively (protection against and increased likelihood of $I_{\text{CaL}}$ reactivation during AP repo-
larization, respectively). Despite the enhancement of AP triangulation associated with large $\tau_{\text{fast}}$ values, no afterdepolarizations were observed in the simulations for 60% changes in $I_{\text{CaL}}$, $I_{\text{Ks}}$, maximal conductance, and $I_{\text{Kr}}$ maximal conductance, although a 10-fold increase in $\tau_{\text{fast}}$ was obtained for a 60% reduction in $\tau_f$.

Regarding the slow phase of APD adaptation, Fig. 6 shows that $I_{\text{NaK}}$ inhibition results in an increase in $\tau_{\text{slow}}$ and also an increased $\rho$ and $\delta$, suggesting the increased likelihood of EAD generation (24, 27, 42). Indeed, $I_{\text{NaK}}$ inhibition by 30% in simulations and by 0.6 M strophanthin G in experiments results in an increase in $\delta$ from 1.11 to 1.15 and from 1.20 to
Fig. 8. A: effect of Na\(^+/\)K\(^+\) pump inhibition on the slow phase of APD rate adaptation. A: simulated (left) and experimental (right) APD adaptation in control (solid line) and for Na\(^+/\)K\(^+\) pump inhibition (dotted line) by 10–20–30% in simulated human ventricular cardiomyocytes and by 0.2 (top) and 0.6 μM (bottom) strophanthin G (Stroph) in canine experiments. Experimental curves represent average over experiments. B: early afterdepolarization generated following CL increase from 600 to 1,000 ms for simulated 60% I\(_{\text{NaK}}\) inhibition. C–G: corresponding time course of [Ca\(^{2+}\)], I\(_{\text{rel}}\), I\(_{\text{NaCa}}\), I\(_{\text{CaL}}\) and calcium-dependent inactivation gate f\(_{\text{calc}}\) of I\(_{\text{CaL}}\). See main text for definitions of abbreviations. V, voltage.
APD rate adaptation is defined as protracted when associated characterization using exponential functions. Based on our results, APD adaptation dynamics and EADs, which prevent its characterization using exponential functions. Based on our results, APD rate adaptation is defined as protracted when associated $\tau_{\text{slow}} > 380$ s. The mechanisms of EAD formation are the same in both humans and dogs: severe $I_{\text{NaK}}$ inhibition results in an increase in $[\text{Na}^+]_i$, and thus in $I_{\text{NaCa}}$-mediated calcium influx (Fig. 8C), which increases $[\text{Ca}^{2+}]_i$ and calcium release from the sarcoplasmic reticulum ($I_{\text{CaL}}$, Fig. 8D). This gives rise to the enhanced depolarizing current via $I_{\text{NaCa}}$ and $I_{\text{Cal}}$ (Fig. 8, E–G) and, consequently, EAD formation.

**DISCUSSION**

The clinical relevance of ventricular rate adaptation has been emphasized in a number of studies (15, 22, 45) and is highlighted by the frequent involvement of sudden changes in CL in the initiation of lethal arrhythmias. In the present study, a synergistic combination of theoretical and experimental methods is used to investigate the ionic basis of QT and APD HR adaptation and their link to proarrhythmic mechanisms. Simulation predictions on QT and APD adaptation dynamics in humans were validated using experimental and clinical data available in the literature, and key ionic mechanisms of ventricular HR adaptation in humans were identified. Because of limitations in the availability of human tissue and similarities in repolarization mechanisms in humans and dogs, further investigations of the ionic basis of ventricular HR adaptation were performed using a combination of simulations and experiments in humans and dogs. The results show that both QT and APD HR adaptation follow similar dynamics, consisting of two phases, fast and slow, driven by $I_{\text{Cal}}$ and $I_{\text{Ks}}$ and conductances, and $[\text{Na}^+]_i$ dynamics and $I_{\text{NaK}}$, respectively. Our results suggest that protracted QT rate adaptation (defined by $\tau_{\text{slow}} > 380$ s), as measured from the surface ECG of patients at high arrhythmic risk, could be a reflection of adverse ionic changes involving $I_{\text{Cal}}$, $I_{\text{Ks}}$, and $[\text{Na}^+]_i$; dynamics that, upon further deterioration, may facilitate arrhythmia initiation via an increased likelihood of EAD generation.

**Dynamics and Mechanisms of Ventricular HR Adaptation in Humans**

This study shows that simulated QT and APD HR adaptation dynamics in humans are in good qualitative and quantitative agreement with the results reported in experimental and clinical studies (3, 18, 22, 29, 35, 36). The simulation results report two phases, fast and slow, in QT and APD adaptation dynamics, as previously reported in human experiments (18, 29, 35, 36) and also confirmed in experiments performed in this study. The time constants for the two phases in human are $\tau_{\text{fast}} \approx 30$ s and $\tau_{\text{slow}} \approx 2$ min, respectively, in both simulations and experiments, in this study and in the literature (18, 36). Similar adaptation dynamics are found in dogs, with a slightly longer adaptation time compared with that in humans.

Our simulation results identify $I_{\text{CaL}}$ and $I_{\text{Ks}}$ properties as the main ionic determinants of the fast rate-dependent APD changes in humans, with $I_{\text{CaL}}$ inactivation (Fig. 5A) playing a major role, as reported in previous studies for humans (31), for guinea pigs and rabbits (39), and for canine Purkinje fibers (6). In addition, our results show that $I_{\text{Ks}}$ activation kinetics also contribute to the fast rate-dependent APD shortening (Fig. 5A), as previously suggested (8, 13, 14).

Importantly, we also demonstrate that $[\text{Na}^+]_i$ dynamics play a key role in the slow phase of APD adaptation (Fig. 5). $I_{\text{NaK}}$ inhibition, as it occurs in ischemia and heart failure patients, results in slower $[\text{Na}^+]_i$ dynamics and delayed APD accommodation. The importance of $I_{\text{NaK}}$ in the slow phase of APD adaptation was previously suggested in animal species such as dogs and guinea pigs (6, 10, 11, 14) but not in humans. Our study quantifies it and confirms it for humans. In addition, we show that it is primarily due to the role of $I_{\text{NaK}}$ in regulating $[\text{Na}^+]_i$ dynamics, and, indirectly, $[\text{Ca}^{2+}]_i$ dynamics by the Na/Ca exchanger, rather than to alterations in the electrogenic $I_{\text{NaK}}$ current.

**Ventricular rate adaptation as an indicator of arrhythmic risk**. Following a thorough validation of the simulated rate adaptation dynamics described in Ventricular Rate Adaptation, computer simulations were used to explore the link between protracted HR adaptation and increased arrhythmic risk, as previously suggested (22, 35). The main preclinical arrhythmic risk biomarkers, namely, AP triangulation, probability of $I_{\text{Cal}}$ reactivation, and APDR, were evaluated for conditions that lead to delayed APD adaptation, to quantify risk of occurrence of repolarization instabilities such as EADs and/or alternans (5, 44).

As discussed in Ventricular Rate Adaptation, delayed APD adaptation could be caused by an increase in $\tau_{\text{fast}}$ (via a moderate reduction in $\tau_{\text{f}}$ or $\tau_{\text{xs}}$ or severe $I_{\text{Cal}}$ maximal conductance block) or in $\tau_{\text{slow}}$ (via $I_{\text{NaK}}$ inhibition). Reduced $\tau_{\text{f}}$ values have been reported in dogs with chronic atrioventricular block (1), which exhibit a high propensity for EADs and Torsades de Pointes, whereas reduced $\tau_{\text{xs}}$ is caused by a mutation in the KCNQ1 gene that causes short QT syndrome and is associated with high sudden cardiac death rate (4). Our simulations also show that a less-pronounced initial APD rate adaptation is associated with an increased AP triangulation and, in the case of reduced $\tau_{\text{xs}}$, a higher probability of $I_{\text{Cal}}$ reactivation, which facilitates EAD formation (25, 27, 30). Our results are also consistent with experimental results showing that the low incidence of EADs observed following the administration of amiodarone could be related to the ability of the drug to slow $I_{\text{Cal}}$ (43) and decrease $\tau_{\text{fast}}$. Furthermore, in patients who benefit from amiodarone therapy, the efficacy of the drug has been explained by its ability to accelerate QT rate adaptation (37).

Reduced $\tau_{\text{f}}$ or $\tau_{\text{xs}}$ and therefore increased $\tau_{\text{fast}}$, are also associated with APDR slopes flattening, consistent with previous studies (23). The potential of APDR slopes as arrhythmic risk predictors is somewhat controversial. Both experimental and theoretical studies have shown that steep restitution slopes facilitate a spiral wave breakup and a transition from ventricular tachycardia to fibrillation (20, 32). However, conditions associated with flat restitution slopes also allow wave break (9, 16) and could favor reentrant wave stability (17, 19). Thus large $\tau_{\text{fast}}$ values could also be associated with an increased...
arrhythmic risk due to the increased likelihood of the establishment of reentrant activity.

Both our simulation and experimental results show that $I_{\text{NaK}}$ plays a key role in determining $\tau_{\text{slow}}$. Large $\tau_{\text{slow}}$ due to $I_{\text{NaK}}$ inhibition is associated with an increase in AP triangulation and in the likelihood of $I_{\text{CaL}}$ reactivation (Fig. 6), indicating an increased risk of EAD formation. Large $\tau_{\text{slow}}$ values are also associated with flat APDR slopes, which could favor the stability of reentrant circuits and thus could increase arrhythmic risk.

Our simulations show that, both in humans and dogs, EADs develop for 60% $I_{\text{NaK}}$ inhibition, a degree of inhibition observed in ischemic disease and heart failure patients treated with digitals (7). In the experiments of $I_{\text{NaK}}$ inhibition with 0.2 or 0.6 μM strophanthid G performed in the present study, no EADs were observed; however, the degree of drug-induced $I_{\text{NaK}}$ inhibition is unknown and may be below 60%. Additionally, the lack of EADs in the experiments might be explained by the electrophysiological differences between the experimental (canine papillary muscle) and simulated preparations (canine Epi and human Endo/Mid/Epi tissue).

Limitations of the Study

In our study, a human ventricular model was used to explore ventricular rate adaptation dynamics and simulation predictions were validated using experimental and clinical data from the literature and in a limited set of experiments in humans performed in this study. Additional experiments and simulations were performed in dogs because of its similarities with humans in repolarization mechanisms. Our experimental and theoretical results obtained in dogs and humans are qualitatively similar, although quantitative differences exist that could be due to true animal species differences, differences in experimental conditions, or model limitations. First, differences exist in $I_{\text{K1}}$ and $I_{\text{Ks}}$ in canine versus human cardiac ventricular tissue (28), which would lead to differences in ventricular rate adaptation. Second, the human model (38) does not include a description of the late sodium current and its $I_{\text{Ks}}$ conductance was defined based on APD measurements, which could explain a larger contribution of $I_{\text{Ks}}$ to APD adaptation in simulations compared with experiments. Despite these limitations, the present study provides new insights into the mechanisms of ventricular rate adaptation and its link to proarrhythmic risk in humans through a challenging combination of theoretical and experimental work.

GRANTS

This study was financially supported by European Commission preDICT Grant DG-INSFO-224381; a United Kingdom Medical Research Council Career Development award (to B. Rodríguez); a Royal Society Visiting Fellowship and International Joint Project (to E. Pueyo and B. Rodríguez); Ministerio de Ciencia e Innovación fellowships and from Caja de Ahorros de la Immaculada, Spain (to E. Pueyo); Ministerio de Ciencia e Innovación, Spain, Grant TEC-2007-68076-C02-02 (to E. Pueyo and P. Laguna); a János Bolyai research scholarship (to I. Baczkó); and Hungarian National Research Foundation Grant OTKA-CNK-77855.

DISCLOSURES

No conflicts to disclose.

REFERENCES